Modulation of Melatonin Receptors Regulates Reproductive Physiology: The Impact of Agomelatine on the Estrus Cycle, Gestation, Offspring, and Uterine Contractions in Rats

Agomelatine is a pharmaceutical compound that functions as an agonist for melatonin receptors, with a particular affinity for the MT1 and MT2 receptor subtypes. Its mode of action is integral to the regulation of diverse physiological processes, encompassing the orchestration of circadian rhythms, s...

Full description

Saved in:
Bibliographic Details
Published in:Physiological research 2023-12, Vol.72 (6), p.793-807
Main Authors: Kacar, E, Tan, F, Sahinturk, S, Zorlu, G, Serhatlioglu, I, Bulmus, O, Ercan, Z, Kelestimur, H
Format: Article
Language:English
Subjects:
Circadian rhythm
Circadian rhythms
Estrus cycle
Females
Fetuses
Gestation
Gestational age
Hormones
Laboratory animals
Melatonin
Melatonin receptors
Myometrium
Offspring
Ovaries
Oxytocin
Physiology
Pregnancy
Puberty
Reproductive system
Sexual behavior
Sleep and wakefulness
Uterus
Vagina
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Agomelatine is a pharmaceutical compound that functions as an agonist for melatonin receptors, with a particular affinity for the MT1 and MT2 receptor subtypes. Its mode of action is integral to the regulation of diverse physiological processes, encompassing the orchestration of circadian rhythms, sleep-wake cycles, and mood modulation. In the present study, we delve into the intricate interplay between agomelatine and the modulation of estrus cycles, gestation periods, offspring numbers, and uterine contractions, shedding light on their collective impact on reproductive physiology. Both in vivo and in vitro experiments were performed. Wistar Albino rats, divided into four groups: two non-pregnant groups (D1 and D2) and two pregnant groups (G1 and G2). The D1 and G1 groups served as control groups, while the D2 and G2 groups received chronic agomelatine administration (10 mg/kg). Uterine contractions were assessed in vitro using myometrial strips. Luzindole, a melatonin receptor antagonist, was employed to investigate the pathway mediating agomelatine's effects on uterine contractions. In in vivo studies, chronic agomelatine administration extended the diestrus phase (p
ISSN:0862-8408
1802-9973
DOI:10.33549/physiolres.935064